Abstract:Background: Tuberculosis (TB) preventive therapy (TPT) is an essential component of care for people living with HIV (PLHIV). We compared efficacy, safety, completion, and drug-resistant TB risk for currently recommended TPT regimens through a systematic review and network meta-analysis (NMA) of randomized trials. Methods and findings: We searched MEDLINE, Embase, and the Cochrane Library from inception through June 9, 2020 for randomized controlled trials (RCTs) comparing 2 or more TPT regimens (or placebo/no treatment) in PLHIV. Two independent reviewers evaluated eligibility, extracted data, and assessed the risk of bias. We grouped TPT strategies as follows: placebo/no treatment, 6 to 12 months of isoniazid, 24 to 72 months of isoniazid, and rifamycin-containing regimens. A frequentist NMA (using graph theory) was carried out for the outcomes of development of TB disease, all-cause mortality, and grade 3 or worse hepatotoxicity. For other outcomes, graphical descriptions or traditional pairwise meta-analyses were carried out as appropriate. The potential role of confounding variables for TB disease and all-cause mortality was assessed through stratified analyses. A total of 6,466 unique studies were screened, and 157 full texts were assessed for eligibility. Of these, 20 studies (reporting 16 randomized trials) were included. The median sample size was 616 (interquartile range [IQR], 317 to 1,892). Eight were conducted in Africa, 3 in Europe, 3 in the Americas, and 2 included sites in multiple continents. According to the NMA, 6 to 12 months of isoniazid were no more efficacious in preventing microbiologically confirmed TB than rifamycin-containing regimens (incidence rate ratio [IRR] 1.0, 95% CI 0.8 to 1.4, p = 0.8); however, 6 to 12 months of isoniazid were associated with a higher incidence of all-cause mortality (IRR 1.6, 95% CI 1.2 to 2.0, p = 0.02) and a higher risk of grade 3 or higher hepatotoxicity (risk difference [RD] 8.9, 95% CI 2.8 to 14.9, p = 0.004). Finally, shorter regimens were associated with higher completion rates relative to longer regimens, and we did not find statistically significant differences in the risk of drug-resistant TB between regimens. Study limitations include potential confounding due to differences in posttreatment follow-up time and TB incidence in the study setting on the estimates of incidence of TB or all-cause mortality, as well as an underrepresentation of pregnant women and children. Conclusions: Rifamycin-containing regimens appear safer and at least as effective as isoniazid regimens in preventing TB and death and should be considered part of routine care in PLHIV. Knowledge gaps remain as to which specific rifamycin-containing regimen provides the optimal balance of efficacy, completion, and safety.

Isoniazid preventive therapy for postrenal transplant tuberculosis: a systematic review

IGRA-based INH regimen for prevention of active tuberculosis after kidney transplantation: a single-center retrospective study

Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis

The effectiveness of isoniazid preventive treatment against tuberculosis among contacts of multidrug-resistant tuberculosis: A systematic review and individual-participant meta-analysis

Screening for Latent Tuberculosis Infection in Solid Organ transplant recipients to predict active disease: a systematic review and meta-analysis of diagnostic studies

Impact of Isoniazid Preventive Therapy on Tuberculosis Incidence and Predictors of Tuberculosis Among People Living With HIV/AIDS at Debre Tabor General Hospital, Northwest Ethiopia

Nontuberculous Mycobacterium Infection in Renal Transplant Recipients: a Systematic Review.

Tuberculosis treatment without rifampin in kidney/kidney–pancreas transplantation: A case series report

Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children

Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data

Tuberculosis in Kidney Transplant Recipients: A Nationwide Cohort in a Low Tuberculosis Incidence Country

Clinical Analysis of Pulmonary Tuberculosis Infection in Renal Transplantation Recipients

Mycobacterium tuberculosis after liver transplantation: Management and guidelines for prevention

Meta-analysis of Preventive Effects of Hepatoprotective on Liver Damage in Patients Undergoing Initial Treatment for Tuberculosis

Systematic Review of the Impact of Protease Inhibitor-Based Combination Antiretroviral Therapy on Renal Transplant Outcomes in Recipients Living with HIV Infection

A clinical analysis of post-renal transplant pulmonary infection

Effectiveness and safety of tuberculosis preventive treatment for contacts of multidrug-resistant tuberculosis patients: A systematic review and Meta-analysis

Treatment of Asymptomatic Bacteriuria after Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Kidney transplantation in patients on anti‐tubercular therapy: A single centre observational study

Isoniazid preventive therapy during infancy does not adversely affect growth among HIV-exposed uninfected children: Secondary analysis of data from a randomized controlled trial

Isoniazid preventive therapy utilization rate and associated factors in adult HIV/AIDS patients in Jimma University Specialized Hospital ART clinic: A cross-sectional study.